Key result
Hydroxychloroquine plus azithromycin linked to a ~28 ms QTc prolongation in SARS-CoV-2 patients.
Why the study?
Does Hydroxychloroquine/Azithromycin combination prolong the QT interval in adult patients with SARS-CoV-2 infection?
Observational (n=84)
No
Does Hydroxychloroquine/Azithromycin combination prolong the QT interval in adult patients with SARS-CoV-2 infection?
Treatment with Hydroxychloroquine and Azithromycin in SARS-CoV-2 patients frequently leads to significant QTc prolongation, with acute renal failure being a strong predictor of extreme prolongation.
Answers are grounded in this paper and cite their sources.
Supports QTc monitoring with hydroxychloroquine/azithromycin in SARS-CoV-2; leaves open arrhythmia outcome impact in observational data.
We report the change in the QT interval in 84 adult patients with SARS-CoV-2 infection treated with Hydroxychloroquine/Azithromycin combination. QTc prolonged maximally from baseline between days 3 and 4. in 30% of patients QTc increased by greater than 40ms. In 11% of patients QTc increased to >500 ms, representing high risk group for arrhythmia. The development of acute renal failure but not baseline QTc was a strong predictor of extreme QTc prolongation.
No takes yet. Share an insight, caveat, or question.
Chorin et al. (2020) conducted an observational in SARS-CoV-2 infection (n=84). Hydroxychloroquine and Azithromycin vs. Baseline (pre-treatment) was evaluated on Maximum QTc interval (ms) (p=<0.001). Treatment with Hydroxychloroquine and Azithromycin significantly prolonged the QTc interval from a baseline of 435 ms to a maximal value of 463 ms in patients with SARS-CoV-2 infection.
Synapse has enriched 10 related papers. Consider them for comparative context: